Your session is about to expire
← Back to Search
Bevacizumab + Temsirolimus for Cancer
Study Summary
This trial is studying the best dose and side effects of bevacizumab and temsirolimus when given alone or with valproic acid or cetuximab to treat patients with a non-cancerous malignancy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 1 & 2 trial • 24 Patients • NCT03010358Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had a bad reaction to temsirolimus or its ingredients in the past.I can take care of myself and perform daily activities.My colorectal cancer has a KRAS mutation.I have not had major surgery in the last 6 weeks.I have not had certain cancer treatments for a specific time before joining this trial.Your platelet count is at least 50,000 per microliter.My advanced cancer hasn't responded to standard treatments, or there are no effective standard treatments available.My blood pressure is controlled and below 140/90 mmHg on medication.I agree to use effective birth control or abstain from sex during and for 90 days after the study.I am mostly able to care for myself but may need occasional help.Your creatinine levels are not more than three times the upper limit of normal.Your total cholesterol level when fasting should be less than 350 mg/dL.I have not had any unexplained bleeding in the last 28 days.Your triglyceride level must be lower than 400 mg/dL.You have had a bad reaction to cetuximab or any of the ingredients in it.I am 16 or younger and can do most activities.I am not currently taking any experimental drugs or other cancer treatments.You have enough infection-fighting white blood cells.I haven't had a stroke, heart attack, or unstable chest pain in the last 6 months.Your AST and ALT levels in the blood should not be more than 5 times the upper limit of normal.I have stopped any CYP3A4 affecting drugs for their required clearance time before starting this therapy.You have had a bad reaction to bevacizumab or any of its ingredients.Your total bilirubin level must be less than or equal to 3.0.
- Group 1: Group III (temsirolimus, bevacizumab)
- Group 2: Group II (temsirolimus, bevacizumab, valproic acid)
- Group 3: Group I (temsirolimus, bevacizumab, cetuximab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What medical issues does Pharmacological Study typically address?
"Pharmacological Study is a beneficial therapeutic approach for organ transplantation, as well as catarrh, psoriasis and advanced non-squamous non-small cell lung cancer."
Is this research initiative currently opening its doors to participants?
"According to clinicaltrials.gov, the recruitment phase for this trial is closed with the last update being posted on July 18th 2022. However, there are 8579 other studies actively recruiting right now; this study was originally listed as of March 16th 2012."
What is the participant quota for this clinical trial?
"This clinical study is not currently open for recruitment. Although it was initially posted on March 16th 2012 and edited most recently on July 18 2022, other medical trials are readily enrolling patients with soft tissue neoplasms (7,956) or Pharmacological Studies (623)."
Has the Pharmacological Study obtained clearance from the FDA?
"Our team at Power assessed the safety of this pharmacological study as a 1 due to its Phase 1 status, signifying sparse clinical data available for both efficacy and safety."
Share this study with friends
Copy Link
Messenger